The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 12, 2020

Filed:

Feb. 09, 2018
Applicants:

Arizona Board of Regents on Behalf of Arizona State University, Scottsdale, AZ (US);

Mayo Foundation for Medical Education and Research, Rochester, MN (US);

Inventors:

Haoyu Wang, New York, NY (US);

Ji Qiu, Chandler, AZ (US);

Joshua LaBaer, Chandler, AZ (US);

Jonathan Leighton, Scottsdale, AZ (US);

Shabana Pasha, Scottsdale, AZ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/564 (2006.01); G01N 33/50 (2006.01); G01N 33/52 (2006.01); G01N 33/543 (2006.01); C12N 15/10 (2006.01); C07K 16/18 (2006.01); C07K 16/30 (2006.01); C07K 16/40 (2006.01);
U.S. Cl.
CPC ...
G01N 33/564 (2013.01); C07K 16/18 (2013.01); C07K 16/30 (2013.01); C07K 16/3069 (2013.01); C07K 16/40 (2013.01); C12N 15/1065 (2013.01); G01N 33/5023 (2013.01); G01N 33/521 (2013.01); G01N 33/5436 (2013.01); G01N 33/54353 (2013.01); G01N 33/54393 (2013.01); C07K 2317/30 (2013.01); C12N 2310/3519 (2013.01); G01N 2800/065 (2013.01);
Abstract

Identification of autoantibodies associated with Crohn's disease useful in diagnosis and management using an innovative protein array technology, namely nucleic acid programmable protein arrays (NAPPA) and applications relating thereto. Overall, reactivity of IgG autoantibodies was stronger than that of IgA autoantibodies; however, IgA autoantibodies showed greater differential reactivity between cases and controls. Four IgA autoantibodies against SNRPB, PRPH, PTTG1 and SNAI1 were newly identified with sensitivities above 15% at 95% specificity, among which anti-SNRPB-IgA had the highest sensitivity of 24.0%. Autoantibodies associated with specific disease subtypes were also found.


Find Patent Forward Citations

Loading…